VisEn launches new imaging agents for R&D biomarkers

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

VisEn Medical launched two new molecular imaging agents, ProSense 750 FAST for imaging cathepsin activity and Neutrophil Elastase 680 FAST for imaging inflammatory elastase activity associated with disease progression and therapeutic response at the European Molecular Imaging meeting in Warsaw, Poland.

The ProSense 750 FAST agent is designed to target a range of cathepsins (B, K, L, S and V), biomarkers in diseases, including atherosclerosis, oncology, pulmonary pathologies and arthritis, said the Bedford, Mass.-based company.

Neutrophil Elastase 680 FAST is a selective neutrophil elastase-activatable agent designed for imaging neutrophil elastase, a protease involved in acute lung injury, acute respiratory distress syndrome, as well as many other inflammatory processes, such as emphysema, cystic fibrosis, COPD, wound healing, rheumatoid arthritis and ischemia reperfusion.